THE EVIDENCE
Semaglutide Weight Loss: The Trial Evidence
-14.9% in STEP 1, sustained at two years, and what happens to the number when you stop — read straight from the studies.
Start here
Semaglutide weight loss has one anchor number: in the STEP 1 trial, people lost an average of 14.9% of their body weight over about 16 months, versus 2.4% on placebo [2]. That is a large effect for a medicine, and it is the figure most others are measured against. The loss holds while the drug continues — a two-year study confirmed it stays [and people keep it off as long as they keep taking it]. The catch is the flip side: when people stop, most of the weight comes back [23]. And in a direct face-off, the newer drug tirzepatide produced a bigger number — about 20% versus 14% [1]. Below, the weight evidence is laid out trial by trial, with no figure left uncited. Nothing here is a dosing plan; it is a reading of what the studies measured.
STEP 1: the anchor result
In STEP 1, 1,961 adults with overweight or obesity and without diabetes received once-weekly subcutaneous semaglutide 2.4 mg or placebo. The mean body-weight change from baseline to week 68 was -14.9% with semaglutide versus -2.4% with placebo — a treatment difference of about 12.4 percentage points [2].
To put that in everyday terms: for someone starting at 220 lb, a 14.9% loss is roughly 33 lb. The trial also tracked the broader picture, and a STEP 1 and 4 exploratory analysis reported improvements across waist circumference, blood pressure, lipids, blood sugar and inflammatory markers versus placebo [15] — the weight number came with cardiometabolic movement, not in isolation.
It is worth being precise about what -14.9% is and is not. It is a mean — an average across nearly two thousand people — so individual results spread out around it; some lost much more, some much less. It is also a result measured under trial conditions, where the dose was titrated on a fixed schedule and participants received structured lifestyle support alongside the drug. The figure is the strongest single anchor for semaglutide's weight effect, but it is an average outcome from a controlled study, not a promise of a specific number for any individual.
Durability: does it last?
Yes — while the drug continues. The continuation evidence comes from STEP 4, a randomized-withdrawal design: after a 20-week run-in on semaglutide, people who continued kept losing weight, while those switched to placebo regained [24]. The two-year STEP 5 program likewise reported sustained, clinically meaningful weight loss over 104 weeks versus placebo.
The corollary is the discontinuation result, and it is the most important caveat for anyone reading the weight numbers. In the STEP 1 trial extension, participants who came off semaglutide regained a mean of roughly 11.6 percentage points of body weight within one year, and the cardiometabolic improvements reverted toward baseline [23]. That is why the literature frames obesity pharmacotherapy as a chronic, ongoing intervention rather than a one-time fix.
How the weight loss happens
The mechanism behind the number is mostly in the brain, not the metabolism. Rodent work showed semaglutide lowers body weight through distributed central nervous system pathways — reaching the brainstem, area postrema, hypothalamic arcuate nucleus and parabrachial nucleus, reducing food intake and altering food preference, without lowering energy expenditure [6].
In plain terms: it reduces hunger and the drive to eat rather than speeding up calorie burn. That matches what people describe anecdotally — quieter "food noise," smaller portions, less interest in sweet and greasy food — which is summarized (clearly labeled as anecdote, not proof) on the Semaglutide effects page. One documented trade-off: a body-composition substudy found the weight lost includes both fat and a meaningful share of lean mass [22], which is why protein and resistance training are active research topics.
Beyond the scale: what else moved
The weight number rarely travels alone, and the trials tracked the rest. Cardiometabolic risk factors improved alongside the loss: a STEP 1 and 4 exploratory analysis reported gains across waist circumference, blood pressure, lipids, blood sugar and inflammatory markers versus placebo [15]. In adults with established cardiovascular disease and obesity but no diabetes, that translated into hard outcomes — a 20% reduction in major adverse cardiovascular events in SELECT (HR 0.80; 95% CI 0.72-0.90; P<0.001) [3], and in type 2 diabetes with chronic kidney disease, a 24% reduction in major kidney events in FLOW (HR 0.76; 95% CI 0.66-0.88) [5].
The through-line is worth stating plainly: in semaglutide's evidence base, the weight effect is the lever, and several distinct clinical benefits hang off it rather than off the scale number alone. The same body-composition substudy that anchors the lean-mass caveat is part of this accounting — the loss includes both fat and a meaningful share of lean mass [22], which is why preserving muscle through protein and resistance training is an active research question rather than a settled one. The cardiometabolic gains, in other words, come bundled with a trade-off that the trials measured rather than hid.
Weight loss vs tirzepatide
The most-asked comparison has a clear answer on this endpoint. In SURMOUNT-5, the 2025 head-to-head in 751 adults with obesity, tirzepatide produced -20.2% versus semaglutide's -13.7% at 72 weeks — about a 6.5 percentage-point gap, significant at P<0.001 [1].
So for maximal weight loss specifically, the direct trial favors tirzepatide. Semaglutide's counterweight is not on the scale but in the outcome trials — the 20% cut in cardiovascular events in SELECT [3] and the 24% cut in kidney events in FLOW [5]. The full side-by-side, including diabetes and blood-sugar comparisons, is on the semaglutide vs tirzepatide page.